-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, GlaxoSmithKline (GSK) and iTeos Therapeutics jointly announced that they will jointly develop and promote the anti-TIGIT antibody EOS-448, which is in phase 1 clinical development
.
The press release issued by GSK pointed out that this collaboration allows GSK to have three different targets (TIGIT, CD96 and PVRIG) related to the CD226 immune checkpoint pathway in research antibody therapies
Today, GlaxoSmithKline (GSK) and iTeos Therapeutics jointly announced that they will jointly develop and promote the anti-TIGIT antibody EOS-448, which is in phase 1 clinical development
Preliminary studies of GSK have verified the important role of CD226 signaling pathway in oncology
.
Therefore, the company has developed an antibody therapy targeting CD96 GSK'608 and an antibody therapy targeting PVRIG GSK'562
▲ GSK's R&D layout for the CD226 signal path (picture source: reference [2])
EOS-448 developed by iTeos is an anti-TIGIT monoclonal antibody with multiple mechanisms of action
.
Through the cooperation with iTeos, GSK's R&D pipeline will have in-development antibody therapies targeting CD96, TIGIT, and PVRIG, providing more diversified tools for the further construction of cancer immune combination therapies
▲EOS-448 has multiple mechanisms of action (picture source: reference [3])
According to the agreement, iTeos will receive an upfront payment of US$625 million and an additional US$1.
45 billion in potential milestone payments
.
GSK and iTeos will share the development costs and responsibilities of EOS-448